A5004624794- Renal cell carcinoma treatment
- Renal and related cancers
- Cancer Genomics and Diagnostics
- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Single-cell and spatial transcriptomics
- Urinary and Genital Oncology Studies
- Ferroptosis and cancer prognosis
- Economic and Financial Impacts of Cancer
- Prostate Cancer Diagnosis and Treatment
- Urological Disorders and Treatments
- Epigenetics and DNA Methylation
- Immune cells in cancer
- Tissue Engineering and Regenerative Medicine
- Urinary Bladder and Prostate Research
- Cancer Cells and Metastasis
- Cancer Research and Treatments
- MRI in cancer diagnosis
- High-Energy Particle Collisions Research
- Mathematical Biology Tumor Growth
- Extracellular vesicles in disease
- Cancer Diagnosis and Treatment
- Particle physics theoretical and experimental studies
- Quantum Chromodynamics and Particle Interactions
Moffitt Cancer Center
2017-2025
University of South Florida
2021
The Ohio State University
2019-2021
Memorial Sloan Kettering Cancer Center
2016-2019
University of Tampa
2018
Washington University in St. Louis
2014-2017
New York Proton Center
2016-2017
Barnes-Jewish Hospital
2015
Fox Chase Cancer Center
2010-2014
Temple University
2014
Tumor-infiltrating immune cells have been linked to prognosis and response immunotherapy; however, the levels of distinct cell subsets signals that draw them into a tumor, such as expression antigen presenting machinery genes, remain poorly characterized. Here, we employ gene expression-based computational method profile infiltration 24 populations in 19 cancer types. We compare types using an score T find clear renal carcinoma (ccRCC) is among highest for both scores. Using profiles well...
The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor histology risk stratification patients is important in therapy selection. stratify treatment recommendations by histology; first-line ccRCC are also stratified group. To further guide advanced RCC, Panel has categorized all kidney cancer regimens as...
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations the clinical management of patients with clear cell and non–clear renal carcinoma, are intended to assist decision-making. These Insights summarize Panel discussions 2020 update guidelines regarding initial first-line systemic therapy options advanced carcinoma.
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These Insights focus on recent updates to the guidelines, including changes certain systemic therapy relapsed or stage IV RCC. They also discuss addition a new section guidelines that identifies describes most common hereditary RCC syndromes provides genetic testing, surveillance, and/or options who are suspected confirmed have...
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These Insights focus on the systemic therapy options advanced RCC summarize new clinical data evaluated by panel recommended therapies in Version 2.2024 Cancer.
Neoadjuvant chemotherapy (NAC) followed by radical cystectomy improves survival compared with alone for patients bladder cancer. Although gemcitabine cisplatin has become a standard NAC regimen, dose-dense combination of methotrexate, vinblastine, doxorubicin, and (ddMVAC) is being adopted at some institutions.To assess the association neoadjuvant ddMVAC vs regimens downstaging overall among treated cancer.Cross-sectional analysis data extracted from medical records consecutive sample, after...
Chromophobe renal cell carcinoma (chRCC) typically shows ~7 chromosome losses (1, 2, 6, 10, 13, 17, and 21) ~31 exonic somatic mutations, yet carries ~5%-10% metastatic incidence. Since extensive chromosomal can generate proteotoxic stress compromise cellular proliferation, it is intriguing how chRCC, a tumor with low number of develop lethal metastases. Genomic features distinguishing from nonmetastatic chRCC are unknown. An integrated approach, including whole-genome sequencing (WGS),...
We report on a search for elementary particles with charges much smaller than the electron charge using data sample of proton-proton collisions provided by CERN Large Hadron Collider in 2018, corresponding to an integrated luminosity 37.5 fb$^{-1}$ at center-of-mass energy 13 TeV. A prototype scintillator-based detector is deployed conduct first hadron collider sensitive ${\leq}0.1e$. The existence new masses between 20 and 4700 MeV excluded 95% confidence level $0.006e$ $0.3e$, depending...
<h3>Importance</h3> Clinical trials have shown an overall survival (OS) benefit associated with first-line immunotherapy (IT) and combination targeted therapy (TT) IT regimens compared TT among patients metastatic clear cell renal carcinoma (RCC). Generalizability of these findings in a real-world cohort outside clinical trial setting is unclear. <h3>Objective</h3> To assess the association TT, IT, OS RCC. <h3>Design, Setting, Participants</h3> This retrospective propensity-matched study...
Introduction Total pelvic exenteration (TPE) for clinical T4b colorectal cancer (CRC) is associated with significant morbidity. Short (0-30 days)- and intermediate (31-90 days)-term temporal analysis of complication onset not well described, yet needed, to better counsel patients considering TPE. Methods A retrospective cohort study consecutive primary or recurrent CRC undergoing open TPE between 2014 2023 was conducted. Clinicopathologic variables were collected each patient. Postoperative...
577 Background: Approximately 30% of patients with ccRCC present metastatic disease (stage IV) and close to half stage III will recur during follow-up surveillance. Two the most common morbid sites development are brain bone metastasis. Existing treatment guidelines do not recommend routine or directed imaging either initial staging surveillance in absence clinical signs symptoms. A group recurrently altered aberrant splice variants primary tumors associated progression have previously been...
581 Background: Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) represents a promising approach for advanced solid tumor treatment. Historically, the success of TIL in clear renal carcinoma (ccRCC) has been limited by difficulty expanding cytotoxic functional TILs. Hypoxic conditions ccRCC microenvironment have associated with mixed characteristics, including metabolic dysregulation and progression. Given significant role hypoxia progression, we investigated expansion...
Background/Objectives: Prostate cancer (PCa) is the most diagnosed in men worldwide. Early diagnosis of disease provides better treatment options for these patients. Recent studies have demonstrated that plasma-based extracellular vesicle microRNAs (miRNAs) are functionally linked to progression, metastasis, and aggressiveness. The use magnetic resonance imaging (MRI) as standard care an overall assessment prostate disease. Quantitative metrics (radiomics) from MRI provide a evaluation tumor...
We evaluated whether 5hmC signatures in cell-free DNA (cfDNA) are associated with treatment failure to androgen-deprivation therapies (ADT) among men hormone-naive prostate cancer. collected a total of 139 serial plasma samples from 55 cancer patients receiving ADT at 3 time points including baseline (before initiating ADT, n = 55); months (after and disease progression (n 15) within 24 or if no was detected 14). used selective chemical labeling sequencing quantify abundance across the...
Background: Mutations in VHL, PBRM1, SETD2, BAP1, and KDM5C are common clear cell renal carcinoma (ccRCC), presence of certain mutations has been associated with outcomes patients non-metastatic disease. Limited information is available regarding the correlation between genomic alterations metastatic disease, including response to VEGF-targeted therapy. Objective: To explore correlations mutational profiles cancer-specific outcomes, standard agents, cc RCC. Methods: A retrospective review...
We report on the expected sensitivity of dedicated scintillator-based detectors at LHC for elementary particles with charges much smaller than electron charge. The dataset provided by a prototype detector is used to characterize performance and provide an accurate background projection. Detector designs, including novel slab configuration, are considered data taking period start in 2022 (Run 3) high luminosity LHC. With Run 3 dataset, existence new masses between 10 MeV 45 GeV could be...